Evaluation of the combined effect of Mahatriphladi Ghrita Nasya, Tarpana, Pana and Rakta-mokshana in Adhimantha (POAG)
Trial Snapshot
- Phase
- Phase 1/2
- Status
- Recruiting
- Sponsor
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- SUBJECTIVE PARAMETER
Study Overview
Brief Summary
This study is a randomized, open-labeled, parallel-group, clinical trial, to the evaluation of the combined effect of Mahatriphladi ghrita Nasya, Tarpana, pana and Rakta-mokshana in Adhimantha (POAG). patients of Adhimantha (POAG) will be selected from the OPD/IPD of shalakya department of Patanjali ayurvedic hospital, Haridwar, Uttarakhand and shri krishna eye institute Haridwar. The study will be conducted on a total of 30 patients (15 patients in each group) based on inclusion and exclusion criteria depending on the detailed clinical history, physical examination, and other necessary investigation and irrespective of their gender, caste, or creed.
Study Design
- Study Type
- Interventional
- Allocation
- Computer generated randomization
- Masking
- Open Label
Eligibility Criteria
- Ages
- 30.00 Year(s) to 70.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •Age 30 To 70 years
- •Patients of either sex.
- •Patients of POAG having IOP < 21mmHg and IOP > 21 mmHg.
- •Visual acuity more than 6/60 and clear media.
- •Patients of POAG.
Exclusion Criteria
- •1.Age below 30 years and above 70 years.
- •Visual acuity less than 6/60
- •Secondary and developmental Glaucoma including exfoliative glaucoma, pigmentary glaucoma,trauma-induced, inflammatory glaucoma, family history of glaucoma
- •Evidence of any anterior segment pathology like conjunctivitis, keratitis, or acute uveitis.
- •History of opaque ocular media (as in cataracts, corneal opacities, vitreous opacities).
- •Pregnant women 7.Any malignancy, uncontrolled diabetes, uncontrolled hypertension.
- •Contraindicated for Nasya.
- •10.Contraindicated for Tarpana.
- •Contraindicated for Rakta-mokshana (jalaukavcharan).
Outcomes
Primary Outcomes
SUBJECTIVE PARAMETER
Time Frame: for subjective parameter 1st and 90th day
1.Blurred vision
Time Frame: for subjective parameter 1st and 90th day
2.Frequent change of presbyopic glasses
Time Frame: for subjective parameter 1st and 90th day
5.Headache
Time Frame: for subjective parameter 1st and 90th day
3.Delayed dark adaptation
Time Frame: for subjective parameter 1st and 90th day
4.Visual field defect
Time Frame: for subjective parameter 1st and 90th day
Secondary Outcomes
- OBJECTIVE PARAMETERS: -(1.Visual Acuity using Snellen’s chart)